Evidence map›Paper›PMID 42321184›Full record

ArticleNature communications2026

Molecular mechanisms of transhydrogenase activity and allosteric regulation in eukaryotic type II PHGDH Ser33.

Sebastian Perrone, Javier O Cifuente, Leonardo Mastrella, Alberto Marina, Beatriz Trastoy, Julia Becker-Kettern, Jean-François Conrotte, Adrià Alcaide-Jiménez, Francisco Corzana, Enrico Glaab and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sebastian Perrone *Structural Glycobiology Laboratory, Biobizkaia Health Research Institute, Cruces University Hospital, Barakaldo, Bizkaia, Spain.ORCID http://orcid.org/0000-0002-1219-6579
Javier O Cifuente *Instituto Biofisika (UPV/EHU, CSIC), University of the Basque Country, Leioa, Spain.ORCID http://orcid.org/0000-0001-5420-121X
Leonardo MastrellaStructural Glycobiology Laboratory, Biobizkaia Health Research Institute, Cruces University Hospital, Barakaldo, Bizkaia, Spain.
Alberto MarinaStructural Glycobiology Laboratory, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain.ORCID http://orcid.org/0000-0001-7822-0503
Beatriz TrastoyStructural Glycoimmunology Laboratory, Biobizkaia Health Research Institute, Cruces University Hospital, Barakaldo, Bizkaia, Spain.ORCID http://orcid.org/0000-0002-2178-732X
Julia Becker-KetternLuxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
Jean-François ConrotteLuxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
Adrià Alcaide-JiménezStructural Glycobiology Laboratory, Department of Structural and Molecular Biology; Molecular Biology Institute of Barcelona (IBMB), Spanish National Research Council (CSIC), Barcelona, Catalonia, Spain.ORCID http://orcid.org/0000-0002-1015-6469
Francisco CorzanaDepartamento Química and Instituto de Investigación en Química de la Universidad de La Rioja (IQUR) Universidad de La Rioja, Logroño, Spain.ORCID http://orcid.org/0000-0001-5597-8127
Enrico GlaabLuxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.ORCID http://orcid.org/0000-0003-3977-7469
Marcelo E GuerinStructural Glycobiology Laboratory, Biobizkaia Health Research Institute, Cruces University Hospital, Barakaldo, Bizkaia, Spain. mrccri@ibmb.csic.es.ORCID http://orcid.org/0000-0001-9524-3184
Carole L LinsterLuxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg. carole.linster@uni.lu.ORCID http://orcid.org/0000-0001-7143-0719

Funding

Rationalizing glycoengineering strategies for immunotherapeutic antibodiesR01AI149297 · NIAID · EMORY UNIVERSITY · PI JEFFREY Victor RAVETCH, ERIC JOHN SUNDBERG · 2020 to 2026
$3.7M
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID) R01AI149297NIAID NIH HHS R01 AI149297
6 · The paper itself

Abstract

L-serine is a critical structural constituent of proteins and membrane phospholipids, playing major roles in cell signaling, metabolism and development. L-Serine is synthesized through a conserved de novo pathway starting from the glycolytic intermediate 3-phosphoglycerate (PGA), being oxidized by 3-phosphoglycerate dehydrogenase (PHGDH) into 3-phosphohydroxypyruvate (PHP). In certain organisms, PHGDH operates as a transhydrogenase using α-ketoglutarate rather than NAD

Indexed as

Phosphoglycerate DehydrogenaseSaccharomyces cerevisiaeSaccharomyces cerevisiae ProteinsAllosteric RegulationCrystallography, X-RayGlutaratesGlyceric AcidsKineticsMolecular Dynamics SimulationNADPhylogenyPyruvatesSerine3-phosphoglycerateGlutaratesGlyceric Acidshydroxypyruvic acidNADPhosphoglycerate DehydrogenasePyruvatesSaccharomyces cerevisiae ProteinsSerine

Identifiers

PMID42321184
PMCPMC13434204

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.